AIP
VRDN icon

Ameritas Investment Partners’s Viridian Therapeutics VRDN Stock Holding History

Ameritas Investment Partners’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$151K Buy
8,198
+1,712
+26% +$27.6K ﹤0.01% 1579
2026
Q1 		$127K Hold
6,486
– – ﹤0.01% 1540
2025
Q4 		$202K Buy
6,486
+621
+11% +$17K 0.01% 1253
2025
Q3 		$127K Sell
5,865
-1,228
-17% -$22.1K ﹤0.01% 1539
2025
Q2 		$99.2K Sell
7,093
-553
-7% -$7.5K ﹤0.01% 1766
2025
Q1 		$103K Hold
7,646
– – ﹤0.01% 1682
2024
Q4 		$147K Buy
7,646
+1,516
+25% +$33K ﹤0.01% 1519
2024
Q3 		$139K Hold
6,130
– – ﹤0.01% 1572
2024
Q2 		$79.8K Buy
6,130
+1,169
+24% +$16.2K ﹤0.01% 1871
2024
Q1 		$86.9K Buy
4,961
+799
+19% +$15.5K ﹤0.01% 1826
2023
Q4 		$90.6K Hold
4,162
– – ﹤0.01% 1806
2023
Q3 		$63.8K Buy
4,162
+677
+19% +$12.9K ﹤0.01% 1950
2023
Q2 		$82.9K Buy
3,485
+459
+15% +$11.8K ﹤0.01% 1722
2023
Q1 		$77K Hold
3,026
– – ﹤0.01% 1701
2022
Q4 		$108K Buy
3,026
+1,091
+56% +$25.1K ﹤0.01% 1537
2022
Q3 		$39K Hold
1,935
– – ﹤0.01% 2159
2022
Q2 		$22K Buy
+1,935
New +$26K ﹤0.01% 2516
2019
Q2 		– Sell
-74
Closed -$3K – 3108
2019
Q1 		$3K Hold
74
– – ﹤0.01% 2923
2018
Q4 		$3K Hold
74
– – ﹤0.01% 2920
2018
Q3 		$6K Hold
74
– – ﹤0.01% 2934
2018
Q2 		$7K Hold
74
– – ﹤0.01% 2905
2018
Q1 		$8K Buy
+74
New +$8.04K ﹤0.01% 2795

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Ameritas Investment Partners's VRDN Position: Q2 2026 in Review

Ameritas Investment Partners increased its Viridian Therapeutics (VRDN) stake by 26% in Q2 2026, buying an estimated $27.6K and bringing the position to 8,198 shares worth $151K. The position accounts for ﹤0.01% of the portfolio, ranked #1579.

Ameritas Investment Partners first reported a position in VRDN in Q1 2018 and has held it in 22 quarters since. The position peaked at $202K in Q4 2025. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Ameritas Investment Partners held 8,198 shares of Viridian Therapeutics worth $151K as of Q2 2026.
  • Ameritas Investment Partners bought 1,712 Viridian Therapeutics shares in Q2 2026, an estimated $27.6K.
  • Viridian Therapeutics made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q2 2026, its #1579 holding.
  • Ameritas Investment Partners first reported a position in Viridian Therapeutics in Q1 2018 and has held it in 22 quarters since.
  • Ameritas Investment Partners's Viridian Therapeutics position peaked at $202K in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Ameritas Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.